Skip to content

Effect of postoperative prophylactic high-flow nasal oxygen therapy on postoperative oxygenation in morbid obese patients undergoing laparoscopic gastric volume reduction surgery

Effect of postoperative prophylactic high-flow nasal oxygen therapy on postoperative oxygenation in morbid obese patients undergoing laparoscopic gastric volume reduction surgery

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400091922
Enrollment
Unknown
Registered
2024-11-06
Start date
2024-08-14
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity Metabolic Disease

Interventions

Experimental group(H1):Postoperative nasal hyperflow oxygen therapy respiratory support (40L/min,30min)
Experimental group(H2):Postoperative nasal hyperflow oxygen therapy respiratory support (40L/min,60min)
Experimental group(H3):Postoperative nasal hyperflow oxygen therapy respiratory support (60L/min,30min)
Experimental group(H4):Postoperative nasal hyperflow oxygen therapy respiratory support (60L/min,60min)
Control group:Postoperative oxygen breathing support with a common mask(50L/min,60min)

Sponsors

First Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing elective laparoscopic gastric volume reduction surgery; 2. ASA CLASS I-III; 3.BMI>= 35 kg/m^2; 4. Surgery time>= 2 hours; 5. Age 18-65 years old; 6. Normal communication; 7. Voluntarily take the test and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Emergency surgery; 2. Previous history of chronic obstructive pulmonary disease or asthma resulting in limited daily activities, history of neuromuscular dysfunction, heart failure (NYHA > Grade 2), restrictive pulmonary disease (TVC reduced by more than 20%), or symptoms of upper respiratory tract infection or pulmonary infection in the past 4 weeks, chest X-ray indicating pneumonia; 3.The presence of tracheotomy and any nasal or facial defects that may prevent the use of high-flow oxygen therapy or masks; 4. Allergic to the anesthetic drugs used in the study; 5. Pregnant or lactating women; 6. Inability to understand oral or written information;

Design outcomes

Primary

MeasureTime frame
Oxygenation index (Pao2/FiO2) after oxygen therapy;

Secondary

MeasureTime frame
Incidence and severity of postoperative pulmonary complications;Perioperative pulmonary ultrasound score;Postoperative dyspnea degree;Perioperative inflammatory indicators;Ultrasonic measurement of diaphragmatic mobility, thickness and thickening fraction after surgery;the incidence of postoperative hypoxia ;The incidences of postoperative subclinical respiratory depression;The incidences of postoperative severe hypoxia;Postoperative modified Aldrete score;

Countries

China

Contacts

Public ContactKe Chen;Zihui Xu

First Affiliated Hospital of Anhui Medical University

hbchenke@163.com+86 138 6590 6580

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026